RENALYTIX AI PLC-ADR (RNLX) Stock Price & Overview
NASDAQ:RNLX • US75973T1016
Current stock price
The current stock price of RNLX is 0.2071 USD. Today RNLX is up by 5.66%. In the past month the price decreased by -26.3%. In the past year, price decreased by -82.15%.
RNLX Key Statistics
- Market Cap
- 17.182M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.61
- Dividend Yield
- N/A
RNLX Stock Performance
RNLX Stock Chart
RNLX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to RNLX. When comparing the yearly performance of all stocks, RNLX is a bad performer in the overall market: 97.34% of all stocks are doing better.
RNLX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RNLX. Both the profitability and financial health of RNLX have multiple concerns.
RNLX Earnings
On May 15, 2024 RNLX reported an EPS of -0.09 and a revenue of 540.00K.
RNLX Forecast & Estimates
5 analysts have analysed RNLX and the average price target is 2.67 USD. This implies a price increase of 1187.44% is expected in the next year compared to the current price of 0.2071.
For the next year, analysts expect an EPS growth of 59.3% and a revenue growth 39.85% for RNLX
RNLX Groups
Sector & Classification
RNLX Financial Highlights
Over the last trailing twelve months RNLX reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 27.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -109.75% | ||
| ROE | -250.48% | ||
| Debt/Equity | 0.41 |
RNLX Ownership
RNLX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 17.94 | 27.381B | ||
| WAY | WAYSTAR HOLDING CORP | 13.2 | 4.342B | ||
| DOCS | DOXIMITY INC-CLASS A | 12.75 | 4.038B | ||
| HTFL | HEARTFLOW INC | N/A | 2.306B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.135B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 232.4 | 1.115B | ||
| TDOC | TELADOC HEALTH INC | N/A | 940.168M | ||
| CERT | CERTARA INC | 10.79 | 864.13M | ||
| SDGR | SCHRODINGER INC | N/A | 849.045M | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 5.88 | 733.1M | ||
| HSTM | HEALTHSTREAM INC | 26.03 | 596.889M | ||
| PHR | PHREESIA INC | 13.28 | 531.65M | ||
| CTEV | CLARITEV CORP | N/A | 288.466M |
Related stock screener links
View all stocks in the Health Care Technology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RNLX
Company Profile
Renalytix Plc engages in the manufacturing of medical devices and equipment. The firm is engaged in a field of bioprognosis for kidney health. The firm has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The company is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Company Info
IPO: 2018-11-06
RENALYTIX AI PLC-ADR
Finsgate, 5-7 Cranwood Street
London SOUTH GLAMORGAN CF64 2EZ GB
CEO: James McCullough
Employees: 102
Phone: 442920710570
RENALYTIX AI PLC-ADR / RNLX FAQ
What does RNLX do?
Renalytix Plc engages in the manufacturing of medical devices and equipment. The firm is engaged in a field of bioprognosis for kidney health. The firm has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The company is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
What is the current price of RNLX stock?
The current stock price of RNLX is 0.2071 USD. The price increased by 5.66% in the last trading session.
Does RENALYTIX AI PLC-ADR pay dividends?
RNLX does not pay a dividend.
What is the ChartMill rating of RENALYTIX AI PLC-ADR stock?
RNLX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for RNLX stock?
RENALYTIX AI PLC-ADR (RNLX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).
What is the employee count for RNLX stock?
RENALYTIX AI PLC-ADR (RNLX) currently has 102 employees.
What is the ownership structure of RENALYTIX AI PLC-ADR (RNLX)?
You can find the ownership structure of RENALYTIX AI PLC-ADR (RNLX) on the Ownership tab.